医学
三阴性乳腺癌
淋巴血管侵犯
乳腺癌
肿瘤科
内科学
阶段(地层学)
化疗
癌症
新辅助治疗
转移
生物
古生物学
作者
Veerle Geurts,Sara Balduzzi,Tessa G. Steenbruggen,Sabine C. Linn,Sabine Siesling,Sunil Badve,Angela DeMichele,Michail Ignatiadis,Roberto A. Leon‐Ferre,Matthew P. Goetz,Antonio C. Wolff,Natalie Klar,Stefan Michiels,Sherene Loi,Sylvia Adams,Hugo M. Horlings,Gabe S. Sonke,Roberto Salgado,Marleen Kok
出处
期刊:JAMA Oncology
[American Medical Association]
日期:2024-06-27
卷期号:10 (8): 1077-1077
被引量:39
标识
DOI:10.1001/jamaoncol.2024.1917
摘要
Results of this study showed that patients with stage I TNBC and high level of sTILs who did not receive neoadjuvant or adjuvant chemotherapy had excellent 10-year BCSS. The findings further support the role of sTILs as integral biomarkers in prospective clinical trials of therapy optimization for this patient population.
科研通智能强力驱动
Strongly Powered by AbleSci AI